Mallinckrodt Delays Generics Spinoff
Executive Summary
Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.
You may also be interested in...
Zydus Ready For Moraiya Reinspection In June
Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Levorphanol Write-Down Dents Zydus in Q2 But Saroglitazar Expectations Build
As returns from levorphanol fall on the back of increased competition, Zydus Cadila writes down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests:
